

Global Tumor Immunotherapy Market Growth (Status and Outlook) 2025-2031

<https://marketpublishers.com/r/G867E7DC2092EN.html>

Date: September 2025

Pages: 159

Price: US\$ 3,660.00 (Single User License)

ID: G867E7DC2092EN

Abstracts

According to this study, the global Tumor Immunotherapy market size will reach US\$ million by 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the "Tumor Immunotherapy Industry Forecast" looks at past sales and reviews total world Tumor Immunotherapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Tumor Immunotherapy sales for 2025 through 2031. With Tumor Immunotherapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Tumor Immunotherapy industry.

This Insight Report provides a comprehensive analysis of the global Tumor Immunotherapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Tumor Immunotherapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Tumor Immunotherapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Immunotherapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Immunotherapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Immunotherapy market by product type, application, key players and key regions and countries.

Segmentation by Type:

- Tumor Infiltrating Lymphocyte (TIL) Treatment
- Engineered T Cell Receptor (TCR) Therapy
- Chimeric Antigen Receptor (CAR) T Cell Therapy
- Natural Killer (NK) Cell Therapy
- Other

Segmentation by Application:

- Biopharmaceutical Company
- Hospital
- Universities And Other Scientific Research Institutions

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Roche

Merck

Novartis

Johnson & Johnson

GlaxoSmithKline

AbbVie

ELI Lilly

Amgen

AstraZeneca

Bristol-Myers Squibb

Kite Pharma

Adaptimmune

Altor Bioscience Corporation

Cellectis

Juno Therapeutics

Takara Bio

Unum Therapeutics

Sunway

Junshi Bio

Cinda Bio

BeiGene

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Tumor Immunotherapy Market Size (2020-2031)
 - 2.1.2 Tumor Immunotherapy Market Size CAGR by Region (2020 VS 2024 VS 2031)
 - 2.1.3 World Current & Future Analysis for Tumor Immunotherapy by Country/Region (2020, 2024 & 2031)
- 2.2 Tumor Immunotherapy Segment by Type
 - 2.2.1 Tumor Infiltrating Lymphocyte (TIL) Treatment
 - 2.2.2 Engineered T Cell Receptor (TCR) Therapy
 - 2.2.3 Chimeric Antigen Receptor (CAR) T Cell Therapy
 - 2.2.4 Natural Killer (NK) Cell Therapy
 - 2.2.5 Other
- 2.3 Tumor Immunotherapy Market Size by Type
 - 2.3.1 Tumor Immunotherapy Market Size CAGR by Type (2020 VS 2024 VS 2031)
 - 2.3.2 Global Tumor Immunotherapy Market Size Market Share by Type (2020-2025)
- 2.4 Tumor Immunotherapy Segment by Application
 - 2.4.1 Biopharmaceutical Company
 - 2.4.2 Hospital
 - 2.4.3 Universities And Other Scientific Research Institutions
 - 2.4.4 Other
- 2.5 Tumor Immunotherapy Market Size by Application
 - 2.5.1 Tumor Immunotherapy Market Size CAGR by Application (2020 VS 2024 VS 2031)
 - 2.5.2 Global Tumor Immunotherapy Market Size Market Share by Application (2020-2025)

3 TUMOR IMMUNOTHERAPY MARKET SIZE BY PLAYER

- 3.1 Tumor Immunotherapy Market Size Market Share by Player
 - 3.1.1 Global Tumor Immunotherapy Revenue by Player (2020-2025)
 - 3.1.2 Global Tumor Immunotherapy Revenue Market Share by Player (2020-2025)
- 3.2 Global Tumor Immunotherapy Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
 - 3.3.1 Competition Landscape Analysis
 - 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion

4 TUMOR IMMUNOTHERAPY BY REGION

- 4.1 Tumor Immunotherapy Market Size by Region (2020-2025)
- 4.2 Global Tumor Immunotherapy Annual Revenue by Country/Region (2020-2025)
- 4.3 Americas Tumor Immunotherapy Market Size Growth (2020-2025)
- 4.4 APAC Tumor Immunotherapy Market Size Growth (2020-2025)
- 4.5 Europe Tumor Immunotherapy Market Size Growth (2020-2025)
- 4.6 Middle East & Africa Tumor Immunotherapy Market Size Growth (2020-2025)

5 AMERICAS

- 5.1 Americas Tumor Immunotherapy Market Size by Country (2020-2025)
- 5.2 Americas Tumor Immunotherapy Market Size by Type (2020-2025)
- 5.3 Americas Tumor Immunotherapy Market Size by Application (2020-2025)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Tumor Immunotherapy Market Size by Region (2020-2025)
- 6.2 APAC Tumor Immunotherapy Market Size by Type (2020-2025)
- 6.3 APAC Tumor Immunotherapy Market Size by Application (2020-2025)
- 6.4 China
- 6.5 Japan

- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe Tumor Immunotherapy Market Size by Country (2020-2025)
- 7.2 Europe Tumor Immunotherapy Market Size by Type (2020-2025)
- 7.3 Europe Tumor Immunotherapy Market Size by Application (2020-2025)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Tumor Immunotherapy by Region (2020-2025)
- 8.2 Middle East & Africa Tumor Immunotherapy Market Size by Type (2020-2025)
- 8.3 Middle East & Africa Tumor Immunotherapy Market Size by Application (2020-2025)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL TUMOR IMMUNOTHERAPY MARKET FORECAST

- 10.1 Global Tumor Immunotherapy Forecast by Region (2026-2031)
 - 10.1.1 Global Tumor Immunotherapy Forecast by Region (2026-2031)
 - 10.1.2 Americas Tumor Immunotherapy Forecast
 - 10.1.3 APAC Tumor Immunotherapy Forecast

- 10.1.4 Europe Tumor Immunotherapy Forecast
- 10.1.5 Middle East & Africa Tumor Immunotherapy Forecast
- 10.2 Americas Tumor Immunotherapy Forecast by Country (2026-2031)
 - 10.2.1 United States Market Tumor Immunotherapy Forecast
 - 10.2.2 Canada Market Tumor Immunotherapy Forecast
 - 10.2.3 Mexico Market Tumor Immunotherapy Forecast
 - 10.2.4 Brazil Market Tumor Immunotherapy Forecast
- 10.3 APAC Tumor Immunotherapy Forecast by Region (2026-2031)
 - 10.3.1 China Tumor Immunotherapy Market Forecast
 - 10.3.2 Japan Market Tumor Immunotherapy Forecast
 - 10.3.3 Korea Market Tumor Immunotherapy Forecast
 - 10.3.4 Southeast Asia Market Tumor Immunotherapy Forecast
 - 10.3.5 India Market Tumor Immunotherapy Forecast
 - 10.3.6 Australia Market Tumor Immunotherapy Forecast
- 10.4 Europe Tumor Immunotherapy Forecast by Country (2026-2031)
 - 10.4.1 Germany Market Tumor Immunotherapy Forecast
 - 10.4.2 France Market Tumor Immunotherapy Forecast
 - 10.4.3 UK Market Tumor Immunotherapy Forecast
 - 10.4.4 Italy Market Tumor Immunotherapy Forecast
 - 10.4.5 Russia Market Tumor Immunotherapy Forecast
- 10.5 Middle East & Africa Tumor Immunotherapy Forecast by Region (2026-2031)
 - 10.5.1 Egypt Market Tumor Immunotherapy Forecast
 - 10.5.2 South Africa Market Tumor Immunotherapy Forecast
 - 10.5.3 Israel Market Tumor Immunotherapy Forecast
 - 10.5.4 Turkey Market Tumor Immunotherapy Forecast
- 10.6 Global Tumor Immunotherapy Forecast by Type (2026-2031)
- 10.7 Global Tumor Immunotherapy Forecast by Application (2026-2031)
 - 10.7.1 GCC Countries Market Tumor Immunotherapy Forecast

11 KEY PLAYERS ANALYSIS

- 11.1 Roche
 - 11.1.1 Roche Company Information
 - 11.1.2 Roche Tumor Immunotherapy Product Offered
 - 11.1.3 Roche Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.1.4 Roche Main Business Overview
 - 11.1.5 Roche Latest Developments
- 11.2 Merck

- 11.2.1 Merck Company Information
- 11.2.2 Merck Tumor Immunotherapy Product Offered
- 11.2.3 Merck Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
- 11.2.4 Merck Main Business Overview
- 11.2.5 Merck Latest Developments
- 11.3 Novartis
 - 11.3.1 Novartis Company Information
 - 11.3.2 Novartis Tumor Immunotherapy Product Offered
 - 11.3.3 Novartis Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.3.4 Novartis Main Business Overview
 - 11.3.5 Novartis Latest Developments
- 11.4 Johnson & Johnson
 - 11.4.1 Johnson & Johnson Company Information
 - 11.4.2 Johnson & Johnson Tumor Immunotherapy Product Offered
 - 11.4.3 Johnson & Johnson Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.4.4 Johnson & Johnson Main Business Overview
 - 11.4.5 Johnson & Johnson Latest Developments
- 11.5 GlaxoSmithKline
 - 11.5.1 GlaxoSmithKline Company Information
 - 11.5.2 GlaxoSmithKline Tumor Immunotherapy Product Offered
 - 11.5.3 GlaxoSmithKline Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.5.4 GlaxoSmithKline Main Business Overview
 - 11.5.5 GlaxoSmithKline Latest Developments
- 11.6 AbbVie
 - 11.6.1 AbbVie Company Information
 - 11.6.2 AbbVie Tumor Immunotherapy Product Offered
 - 11.6.3 AbbVie Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.6.4 AbbVie Main Business Overview
 - 11.6.5 AbbVie Latest Developments
- 11.7 ELI Lilly
 - 11.7.1 ELI Lilly Company Information
 - 11.7.2 ELI Lilly Tumor Immunotherapy Product Offered
 - 11.7.3 ELI Lilly Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)

- 11.7.4 ELI Lilly Main Business Overview
- 11.7.5 ELI Lilly Latest Developments
- 11.8 Amgen
 - 11.8.1 Amgen Company Information
 - 11.8.2 Amgen Tumor Immunotherapy Product Offered
 - 11.8.3 Amgen Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.8.4 Amgen Main Business Overview
 - 11.8.5 Amgen Latest Developments
- 11.9 AstraZeneca
 - 11.9.1 AstraZeneca Company Information
 - 11.9.2 AstraZeneca Tumor Immunotherapy Product Offered
 - 11.9.3 AstraZeneca Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.9.4 AstraZeneca Main Business Overview
 - 11.9.5 AstraZeneca Latest Developments
- 11.10 Bristol-Myers Squibb
 - 11.10.1 Bristol-Myers Squibb Company Information
 - 11.10.2 Bristol-Myers Squibb Tumor Immunotherapy Product Offered
 - 11.10.3 Bristol-Myers Squibb Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.10.4 Bristol-Myers Squibb Main Business Overview
 - 11.10.5 Bristol-Myers Squibb Latest Developments
- 11.11 Kite Pharma
 - 11.11.1 Kite Pharma Company Information
 - 11.11.2 Kite Pharma Tumor Immunotherapy Product Offered
 - 11.11.3 Kite Pharma Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.11.4 Kite Pharma Main Business Overview
 - 11.11.5 Kite Pharma Latest Developments
- 11.12 Adaptimmune
 - 11.12.1 Adaptimmune Company Information
 - 11.12.2 Adaptimmune Tumor Immunotherapy Product Offered
 - 11.12.3 Adaptimmune Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.12.4 Adaptimmune Main Business Overview
 - 11.12.5 Adaptimmune Latest Developments
- 11.13 Altor Bioscience Corporation
 - 11.13.1 Altor Bioscience Corporation Company Information

- 11.13.2 Altor Bioscience Corporation Tumor Immunotherapy Product Offered
- 11.13.3 Altor Bioscience Corporation Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
- 11.13.4 Altor Bioscience Corporation Main Business Overview
- 11.13.5 Altor Bioscience Corporation Latest Developments
- 11.14 Collectis
 - 11.14.1 Collectis Company Information
 - 11.14.2 Collectis Tumor Immunotherapy Product Offered
 - 11.14.3 Collectis Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.14.4 Collectis Main Business Overview
 - 11.14.5 Collectis Latest Developments
- 11.15 Juno Therapeutics
 - 11.15.1 Juno Therapeutics Company Information
 - 11.15.2 Juno Therapeutics Tumor Immunotherapy Product Offered
 - 11.15.3 Juno Therapeutics Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.15.4 Juno Therapeutics Main Business Overview
 - 11.15.5 Juno Therapeutics Latest Developments
- 11.16 Takara Bio
 - 11.16.1 Takara Bio Company Information
 - 11.16.2 Takara Bio Tumor Immunotherapy Product Offered
 - 11.16.3 Takara Bio Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.16.4 Takara Bio Main Business Overview
 - 11.16.5 Takara Bio Latest Developments
- 11.17 Unum Therapeutics
 - 11.17.1 Unum Therapeutics Company Information
 - 11.17.2 Unum Therapeutics Tumor Immunotherapy Product Offered
 - 11.17.3 Unum Therapeutics Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.17.4 Unum Therapeutics Main Business Overview
 - 11.17.5 Unum Therapeutics Latest Developments
- 11.18 Sunway
 - 11.18.1 Sunway Company Information
 - 11.18.2 Sunway Tumor Immunotherapy Product Offered
 - 11.18.3 Sunway Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)
 - 11.18.4 Sunway Main Business Overview

11.18.5 Sunway Latest Developments

11.19 Junshi Bio

11.19.1 Junshi Bio Company Information

11.19.2 Junshi Bio Tumor Immunotherapy Product Offered

11.19.3 Junshi Bio Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)

11.19.4 Junshi Bio Main Business Overview

11.19.5 Junshi Bio Latest Developments

11.20 Cinda Bio

11.20.1 Cinda Bio Company Information

11.20.2 Cinda Bio Tumor Immunotherapy Product Offered

11.20.3 Cinda Bio Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)

11.20.4 Cinda Bio Main Business Overview

11.20.5 Cinda Bio Latest Developments

11.21 BeiGene

11.21.1 BeiGene Company Information

11.21.2 BeiGene Tumor Immunotherapy Product Offered

11.21.3 BeiGene Tumor Immunotherapy Revenue, Gross Margin and Market Share (2020-2025)

11.21.4 BeiGene Main Business Overview

11.21.5 BeiGene Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Tumor Immunotherapy Market Size CAGR by Region (2020 VS 2024 VS 2031) & (\$ millions)

Table 2. Tumor Immunotherapy Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of Tumor Infiltrating Lymphocyte (TIL) Treatment

Table 4. Major Players of Engineered T Cell Receptor (TCR) Therapy

Table 5. Major Players of Chimeric Antigen Receptor (CAR) T Cell Therapy

Table 6. Major Players of Natural Killer (NK) Cell Therapy

Table 7. Major Players of Other

Table 8. Tumor Immunotherapy Market Size CAGR by Type (2020 VS 2024 VS 2031) & (\$ millions)

Table 9. Global Tumor Immunotherapy Market Size by Type (2020-2025) & (\$ millions)

Table 10. Global Tumor Immunotherapy Market Size Market Share by Type (2020-2025)

Table 11. Tumor Immunotherapy Market Size CAGR by Application (2020 VS 2024 VS 2031) & (\$ millions)

Table 12. Global Tumor Immunotherapy Market Size by Application (2020-2025) & (\$ millions)

Table 13. Global Tumor Immunotherapy Market Size Market Share by Application (2020-2025)

Table 14. Global Tumor Immunotherapy Revenue by Player (2020-2025) & (\$ millions)

Table 15. Global Tumor Immunotherapy Revenue Market Share by Player (2020-2025)

Table 16. Tumor Immunotherapy Key Players Head office and Products Offered

Table 17. Tumor Immunotherapy Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 18. New Products and Potential Entrants

Table 19. Mergers & Acquisitions, Expansion

Table 20. Global Tumor Immunotherapy Market Size by Region (2020-2025) & (\$ millions)

Table 21. Global Tumor Immunotherapy Market Size Market Share by Region (2020-2025)

Table 22. Global Tumor Immunotherapy Revenue by Country/Region (2020-2025) & (\$ millions)

Table 23. Global Tumor Immunotherapy Revenue Market Share by Country/Region (2020-2025)

Table 24. Americas Tumor Immunotherapy Market Size by Country (2020-2025) & (\$ millions)

Table 25. Americas Tumor Immunotherapy Market Size Market Share by Country (2020-2025)

Table 26. Americas Tumor Immunotherapy Market Size by Type (2020-2025) & (\$ millions)

Table 27. Americas Tumor Immunotherapy Market Size Market Share by Type (2020-2025)

Table 28. Americas Tumor Immunotherapy Market Size by Application (2020-2025) & (\$ millions)

Table 29. Americas Tumor Immunotherapy Market Size Market Share by Application (2020-2025)

Table 30. APAC Tumor Immunotherapy Market Size by Region (2020-2025) & (\$ millions)

Table 31. APAC Tumor Immunotherapy Market Size Market Share by Region (2020-2025)

Table 32. APAC Tumor Immunotherapy Market Size by Type (2020-2025) & (\$ millions)

Table 33. APAC Tumor Immunotherapy Market Size by Application (2020-2025) & (\$ millions)

Table 34. Europe Tumor Immunotherapy Market Size by Country (2020-2025) & (\$ millions)

Table 35. Europe Tumor Immunotherapy Market Size Market Share by Country (2020-2025)

Table 36. Europe Tumor Immunotherapy Market Size by Type (2020-2025) & (\$ millions)

Table 37. Europe Tumor Immunotherapy Market Size by Application (2020-2025) & (\$ millions)

Table 38. Middle East & Africa Tumor Immunotherapy Market Size by Region (2020-2025) & (\$ millions)

Table 39. Middle East & Africa Tumor Immunotherapy Market Size by Type (2020-2025) & (\$ millions)

Table 40. Middle East & Africa Tumor Immunotherapy Market Size by Application (2020-2025) & (\$ millions)

Table 41. Key Market Drivers & Growth Opportunities of Tumor Immunotherapy

Table 42. Key Market Challenges & Risks of Tumor Immunotherapy

Table 43. Key Industry Trends of Tumor Immunotherapy

Table 44. Global Tumor Immunotherapy Market Size Forecast by Region (2026-2031) & (\$ millions)

Table 45. Global Tumor Immunotherapy Market Size Market Share Forecast by Region

(2026-2031)

Table 46. Global Tumor Immunotherapy Market Size Forecast by Type (2026-2031) & (\$ millions)

Table 47. Global Tumor Immunotherapy Market Size Forecast by Application (2026-2031) & (\$ millions)

Table 48. Roche Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 49. Roche Tumor Immunotherapy Product Offered

Table 50. Roche Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 51. Roche Main Business

Table 52. Roche Latest Developments

Table 53. Merck Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 54. Merck Tumor Immunotherapy Product Offered

Table 55. Merck Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 56. Merck Main Business

Table 57. Merck Latest Developments

Table 58. Novartis Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 59. Novartis Tumor Immunotherapy Product Offered

Table 60. Novartis Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 61. Novartis Main Business

Table 62. Novartis Latest Developments

Table 63. Johnson & Johnson Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 64. Johnson & Johnson Tumor Immunotherapy Product Offered

Table 65. Johnson & Johnson Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 66. Johnson & Johnson Main Business

Table 67. Johnson & Johnson Latest Developments

Table 68. GlaxoSmithKline Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 69. GlaxoSmithKline Tumor Immunotherapy Product Offered

Table 70. GlaxoSmithKline Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 71. GlaxoSmithKline Main Business

Table 72. GlaxoSmithKline Latest Developments

Table 73. AbbVie Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 74. AbbVie Tumor Immunotherapy Product Offered

Table 75. AbbVie Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 76. AbbVie Main Business

Table 77. AbbVie Latest Developments

Table 78. ELI Lilly Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 79. ELI Lilly Tumor Immunotherapy Product Offered

Table 80. ELI Lilly Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 81. ELI Lilly Main Business

Table 82. ELI Lilly Latest Developments

Table 83. Amgen Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 84. Amgen Tumor Immunotherapy Product Offered

Table 85. Amgen Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 86. Amgen Main Business

Table 87. Amgen Latest Developments

Table 88. AstraZeneca Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 89. AstraZeneca Tumor Immunotherapy Product Offered

Table 90. AstraZeneca Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 91. AstraZeneca Main Business

Table 92. AstraZeneca Latest Developments

Table 93. Bristol-Myers Squibb Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 94. Bristol-Myers Squibb Tumor Immunotherapy Product Offered

Table 95. Bristol-Myers Squibb Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 96. Bristol-Myers Squibb Main Business

Table 97. Bristol-Myers Squibb Latest Developments

Table 98. Kite Pharma Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 99. Kite Pharma Tumor Immunotherapy Product Offered

Table 100. Kite Pharma Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)
Table 101. Kite Pharma Main Business
Table 102. Kite Pharma Latest Developments
Table 103. Adaptimmune Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 104. Adaptimmune Tumor Immunotherapy Product Offered
Table 105. Adaptimmune Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)
Table 106. Adaptimmune Main Business
Table 107. Adaptimmune Latest Developments
Table 108. Altor Bioscience Corporation Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 109. Altor Bioscience Corporation Tumor Immunotherapy Product Offered
Table 110. Altor Bioscience Corporation Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)
Table 111. Altor Bioscience Corporation Main Business
Table 112. Altor Bioscience Corporation Latest Developments
Table 113. Cellectis Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 114. Cellectis Tumor Immunotherapy Product Offered
Table 115. Cellectis Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)
Table 116. Cellectis Main Business
Table 117. Cellectis Latest Developments
Table 118. Juno Therapeutics Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 119. Juno Therapeutics Tumor Immunotherapy Product Offered
Table 120. Juno Therapeutics Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)
Table 121. Juno Therapeutics Main Business
Table 122. Juno Therapeutics Latest Developments
Table 123. Takara Bio Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors
Table 124. Takara Bio Tumor Immunotherapy Product Offered
Table 125. Takara Bio Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)
Table 126. Takara Bio Main Business
Table 127. Takara Bio Latest Developments

Table 128. Unum Therapeutics Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 129. Unum Therapeutics Tumor Immunotherapy Product Offered

Table 130. Unum Therapeutics Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 131. Unum Therapeutics Main Business

Table 132. Unum Therapeutics Latest Developments

Table 133. Sunway Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 134. Sunway Tumor Immunotherapy Product Offered

Table 135. Sunway Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 136. Sunway Main Business

Table 137. Sunway Latest Developments

Table 138. Junshi Bio Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 139. Junshi Bio Tumor Immunotherapy Product Offered

Table 140. Junshi Bio Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 141. Junshi Bio Main Business

Table 142. Junshi Bio Latest Developments

Table 143. Cinda Bio Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 144. Cinda Bio Tumor Immunotherapy Product Offered

Table 145. Cinda Bio Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 146. Cinda Bio Main Business

Table 147. Cinda Bio Latest Developments

Table 148. BeiGene Details, Company Type, Tumor Immunotherapy Area Served and Its Competitors

Table 149. BeiGene Tumor Immunotherapy Product Offered

Table 150. BeiGene Tumor Immunotherapy Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 151. BeiGene Main Business

Table 152. BeiGene Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Tumor Immunotherapy Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Tumor Immunotherapy Market Size Growth Rate (2020-2031) (\$ millions)
- Figure 6. Tumor Immunotherapy Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)
- Figure 7. Tumor Immunotherapy Sales Market Share by Country/Region (2024)
- Figure 8. Tumor Immunotherapy Sales Market Share by Country/Region (2020, 2024 & 2031)
- Figure 9. Global Tumor Immunotherapy Market Size Market Share by Type in 2024
- Figure 10. Tumor Immunotherapy in Biopharmaceutical Company
- Figure 11. Global Tumor Immunotherapy Market: Biopharmaceutical Company (2020-2025) & (\$ millions)
- Figure 12. Tumor Immunotherapy in Hospital
- Figure 13. Global Tumor Immunotherapy Market: Hospital (2020-2025) & (\$ millions)
- Figure 14. Tumor Immunotherapy in Universities And Other Scientific Research Institutions
- Figure 15. Global Tumor Immunotherapy Market: Universities And Other Scientific Research Institutions (2020-2025) & (\$ millions)
- Figure 16. Tumor Immunotherapy in Other
- Figure 17. Global Tumor Immunotherapy Market: Other (2020-2025) & (\$ millions)
- Figure 18. Global Tumor Immunotherapy Market Size Market Share by Application in 2024
- Figure 19. Global Tumor Immunotherapy Revenue Market Share by Player in 2024
- Figure 20. Global Tumor Immunotherapy Market Size Market Share by Region (2020-2025)
- Figure 21. Americas Tumor Immunotherapy Market Size 2020-2025 (\$ millions)
- Figure 22. APAC Tumor Immunotherapy Market Size 2020-2025 (\$ millions)
- Figure 23. Europe Tumor Immunotherapy Market Size 2020-2025 (\$ millions)
- Figure 24. Middle East & Africa Tumor Immunotherapy Market Size 2020-2025 (\$ millions)
- Figure 25. Americas Tumor Immunotherapy Value Market Share by Country in 2024
- Figure 26. United States Tumor Immunotherapy Market Size Growth 2020-2025 (\$

millions)

Figure 27. Canada Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 28. Mexico Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 29. Brazil Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 30. APAC Tumor Immunotherapy Market Size Market Share by Region in 2024

Figure 31. APAC Tumor Immunotherapy Market Size Market Share by Type
(2020-2025)

Figure 32. APAC Tumor Immunotherapy Market Size Market Share by Application
(2020-2025)

Figure 33. China Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 34. Japan Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 35. South Korea Tumor Immunotherapy Market Size Growth 2020-2025 (\$
millions)

Figure 36. Southeast Asia Tumor Immunotherapy Market Size Growth 2020-2025 (\$
millions)

Figure 37. India Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 38. Australia Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 39. Europe Tumor Immunotherapy Market Size Market Share by Country in 2024

Figure 40. Europe Tumor Immunotherapy Market Size Market Share by Type
(2020-2025)

Figure 41. Europe Tumor Immunotherapy Market Size Market Share by Application
(2020-2025)

Figure 42. Germany Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 43. France Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 44. UK Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 45. Italy Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 46. Russia Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 47. Middle East & Africa Tumor Immunotherapy Market Size Market Share by
Region (2020-2025)

Figure 48. Middle East & Africa Tumor Immunotherapy Market Size Market Share by
Type (2020-2025)

Figure 49. Middle East & Africa Tumor Immunotherapy Market Size Market Share by
Application (2020-2025)

Figure 50. Egypt Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 51. South Africa Tumor Immunotherapy Market Size Growth 2020-2025 (\$
millions)

Figure 52. Israel Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 53. Turkey Tumor Immunotherapy Market Size Growth 2020-2025 (\$ millions)

Figure 54. GCC Countries Tumor Immunotherapy Market Size Growth 2020-2025 (\$

millions)

Figure 55. Americas Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 56. APAC Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 57. Europe Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 58. Middle East & Africa Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 59. United States Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 60. Canada Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 61. Mexico Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 62. Brazil Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 63. China Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 64. Japan Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 65. Korea Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 66. Southeast Asia Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 67. India Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 68. Australia Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 69. Germany Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 70. France Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 71. UK Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 72. Italy Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 73. Russia Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 74. Egypt Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 75. South Africa Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 76. Israel Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 77. Turkey Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

Figure 78. Global Tumor Immunotherapy Market Size Market Share Forecast by Type (2026-2031)

Figure 79. Global Tumor Immunotherapy Market Size Market Share Forecast by Application (2026-2031)

Figure 80. GCC Countries Tumor Immunotherapy Market Size 2026-2031 (\$ millions)

I would like to order

Product name: Global Tumor Immunotherapy Market Growth (Status and Outlook) 2025-2031

Product link: <https://marketpublishers.com/r/G867E7DC2092EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G867E7DC2092EN.html>